Roche Holding AG (OTCMKTS:RHHBY) Receives $57.00 Consensus Target Price from Analysts

Roche Holding AG (OTCMKTS:RHHBY) has received an average rating of “Hold” from the eleven analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $57.00.

A number of research analysts have commented on the stock. Barclays raised shares of Roche from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Zacks Research raised shares of Roche from a “strong sell” rating to a “hold” rating in a research report on Monday, January 5th. Argus raised shares of Roche from a “hold” rating to a “buy” rating in a research report on Monday, April 6th. TD Cowen reissued a “hold” rating on shares of Roche in a research report on Tuesday, February 10th. Finally, The Goldman Sachs Group raised shares of Roche from a “sell” rating to a “hold” rating in a research report on Thursday, January 15th.

Institutional Investors Weigh In On Roche

Hedge funds have recently made changes to their positions in the stock. Sentinel Trust Co. LBA purchased a new stake in shares of Roche during the 3rd quarter worth $878,000. Meritage Portfolio Management bought a new stake in shares of Roche in the 4th quarter valued at about $4,372,000. Vestmark Advisory Solutions Inc. bought a new stake in shares of Roche in the 3rd quarter valued at about $597,000. Curio Wealth LLC bought a new stake in shares of Roche in the 3rd quarter valued at about $25,000. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of Roche by 23.0% in the 3rd quarter. PNC Financial Services Group Inc. now owns 18,799 shares of the company’s stock valued at $786,000 after buying an additional 3,513 shares in the last quarter.

Roche Stock Up 1.3%

OTCMKTS RHHBY opened at $51.86 on Tuesday. The company’s 50-day moving average price is $52.94 and its 200-day moving average price is $50.64. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.12 and a current ratio of 1.38. Roche has a 12 month low of $35.07 and a 12 month high of $60.85.

Roche News Roundup

Here are the key news stories impacting Roche this week:

• Positive Sentiment: Group sales rose 6% at constant exchange rates in Q1, driven by strong demand for key medicines and diagnostics (Pharmaceuticals +7% CER); management highlights products such as Xolair, Phesgo, Hemlibra, Vabysmo and Ocrevus as growth drivers. Roche reports strong sales growth of +6% at constant exchange rates in Q1
• Positive Sentiment: Roche reaffirmed its full‑year outlook after Q1, signalling management confidence that CER growth and product momentum can offset currency effects. Roche Backs Full-Year View as Quarterly Sales Rise
• Positive Sentiment: Pipeline progress: Roche reported strong data and regulatory activity — Gazyva under FDA review for lupus and positive MS/neurology readouts that support the growth outlook. These advances reduce future revenue risk from biosimilar pressure on legacy products. Roche Highlights Gazyva Progress, Reports Data on Enspryng, MS Drug
• Positive Sentiment: Late‑stage MS drug fenebrutinib showed very strong efficacy in relapsing MS (reports saying relapse rate reduced to roughly one every 17 years), supporting potential long‑term commercial upside if approved. Roche MS Drug Cuts Relapses To Once Every 17 Years But Reports Eight Deaths
• Neutral Sentiment: Management call/transcript provides color on drivers and FX: investors should watch margin and regional mix commentary in the Q1 sales/trading call for near‑term guidance details. Roche Q1 2026 Sales/Trading Call Transcript
• Neutral Sentiment: Analyst coverage notes underlying CER growth (+6%) but flags that biosimilars continue to pressure legacy portfolio; watch product mix and margin trends. RHHBY’s Q1 Results Hit by Currency Headwinds, Sales Up 6% at CER
• Negative Sentiment: Reported sales fell in CHF (‑5%) because of a stronger Swiss franc and other forex effects — this currency drag masks CER growth and can pressure reported revenue and EPS near term. Roche Q1 sales down on forex effects
• Negative Sentiment: Safety/regulatory risk: Roche submitted fenebrutinib to regulators but trial reports show multiple patient deaths (seven‑eight), creating potential approval delays, label restrictions, or commercial headwinds if regulators demand further data. Roche submits MS drug fenebrutinib to regulators despite patient deaths

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.